This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 2 of 9 for:    xencor

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

This study is currently recruiting participants.
See Contacts and Locations
Verified October 2016 by Xencor, Inc.
Chiltern International Inc.
Information provided by (Responsible Party):
Xencor, Inc. Identifier:
First received: March 31, 2016
Last updated: October 3, 2016
Last verified: October 2016
The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.

Condition Intervention Phase
Acute Myelogenous Leukemia B-cell Acute Lymphoblastic Leukemia Blastic Plasmacytoid Dendritic Cell Neoplasm Chronic Myeloid Leukemia, Blast Crisis Biological: XmAb14045 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies

Resource links provided by NLM:

Further study details as provided by Xencor, Inc.:

Primary Outcome Measures:
  • Identification of the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) for first and subsequent infusions [ Time Frame: Baseline Day 1 through Day 56 ]
  • Safety and tolerability as assessed by AEs, vital signs, physical exam findings, clinical laboratory safety assessments, and electrocardiogram (ECG) parameters, and incidence of treatment-emergent AEs [ Time Frame: Baseline Day 1 through Day 56 ]

Estimated Enrollment: 66
Study Start Date: August 2016
Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: XmAb14045 Biological: XmAb14045
Administered IV weekly up to 8 weeks


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of 1 of the following diseases:
  • Primary or secondary AML (including erythroleukemia and eosinophilic leukemia, but excluding acute promyelocytic leukemia)
  • B-cell ALL
  • CML in blast phase, resistant or intolerant to tyrosine kinase inhibitor therapy
  • Patients with relapsed or refractory disease with no available standard therapy
  • ECOG performance status 0-2
  • Not a candidate for, or refusing treatment with hematopoietic stem cell transplantation

Exclusion Criteria:

  • Cytotoxic chemotherapy, radiotherapy, immunotherapy or investigational agent treatment within 2 weeks of first dose of study drug
  • Prior therapy with CD123- or IL-3R-directed immunotherapies, including monospecific and bsAbs, immunoconjugates, or chimeric antigen receptor-modified T-cell therapy
  • Failure to recover from Grade 3 or 4 toxicity from previous treatment (unrelated to malignant bone marrow involvement)
  • Known uncontrolled central nervous system involvement by malignant disease
  • White blood cell (WBC) count ≥10,000/mm3 or symptoms of leukostasis
  • Diagnosis of promyelocytic leukemia
  • Aspartate aminotransferase or alanine aminotransferase at screening >3.0 x upper limit of normal (ULN) unless considered due to leukemic organ involvement
  • Bilirubin >1.5 x ULN, unless prior diagnosis and documentation of leukemic organ involvement, ongoing hemolysis, or Gilbert's syndrome
  • Serum creatinine >2.0 x ULN, or estimated creatinine clearance <40mL/min
  • History or evidence of a clinically unstable/uncontrollable disorder, condition or disease other than primary malignancy, that in the opinion of the Investigator would pose a risk to the patient safety or interfere with the study evaluation
  • Evidence of any active, uncontrolled bacterial, viral, parasitic fungal infections within 1 week of first dose of study drug
  • Positive test for human immunodeficiency virus (HIV) -I or -II antibodies, hepatitis B surface antigen or core antibody, or hepatitis C virus antibody
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02730312

Contact: Wayne Saville, MD 858-480-3410
Contact: Chelsea Johnson, RN 858-480-3891

United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Wendy Stock, MD   
Contact: Howard Weiner    773-702-2084   
United States, Ohio
The Ohio State University Comprehensive Cancer Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Kasturi Ganesh Barki    614-685-6227   
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Farhad Ravandi-Kashani, MD    713-745-0394   
Sponsors and Collaborators
Xencor, Inc.
Chiltern International Inc.
Study Director: Wayne Saville, MD VP, Oncology Clinical Development, Xencor, Inc.
  More Information

Responsible Party: Xencor, Inc. Identifier: NCT02730312     History of Changes
Other Study ID Numbers: XmAb14045-01
Study First Received: March 31, 2016
Last Updated: October 3, 2016
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Xencor, Inc.:
Blast Crisis

Additional relevant MeSH terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Acute
Blast Crisis
Burkitt Lymphoma
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Cell Transformation, Neoplastic
Neoplastic Processes
Pathologic Processes
Epstein-Barr Virus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Lymphoma processed this record on June 26, 2017